Hurvitz Chaim's Form 4 filing
NRX Pharmaceuticals, Inc. (NRXP) · filed Nov 21, 2022
- Accession no.
- 0000950142-22-003233
- Filed
- Nov 21, 2022
- Trade date
- Oct 21-Nov 18, 2022
- Filing delay
- 31 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market purchases total $514.9K. It was filed 31 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0000950142-22-003250 (Nov 23, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hurvitz ChaimCIK 0001630542 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 16, 2022 | Common Stock | PPurchaseAcquired | +287,812 | $0.99 | +$284,933.88 | 287,812 | Direct | |
| Nov 17, 2022 | Common Stock | PPurchaseAcquired | +171,780 | $1.08 | +$185,522.4 | 459,592 | Direct | |
| Nov 18, 2022 | Common Stock | PPurchaseAcquired | +40,408 | $1.10 | +$44,448.8 | 500,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 21, 2022 | Common Stock | AGrant or awardAcquired | +162,660 | – | – | 381,083 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.